Skip to main content
Top
Published in: Journal of Gastrointestinal Cancer 4/2011

01-12-2011 | Mgmt. of Complex Cases in GI Oncology

A Woman with Remotely Treated Pancreas Cancer and New Abdominal Pain: A Discussion of Evaluation and Management

Authors: Andrew S. Epstein, Eileen M. O’Reilly, Maeve Lowery, Ali Shamseddine, Jinru Shia, Sally Temraz, Ashwaq Al-Olayan, Mohamed Naghy, David Kelsen, Manish A. Shah, Ghassan K. Abou-Alfa

Published in: Journal of Gastrointestinal Cancer | Issue 4/2011

Login to get access

Excerpt

Dr. Epstein (New York): A 70-year-old woman with a remotely treated exocrine pancreas cancer presented with right upper quadrant abdominal pain. A CT scan of the abdomen and pelvis revealed multiple bilobar liver lesions of various sizes from 1.3 to 4.9 cm in diameter, new since a scan performed a few years previously (Fig. 1). The patient’s pancreas cancer, diagnosed as adenocarcinoma at that time, was resected 25 years ago at Memorial Sloan-Kettering Cancer Center (MSKCC), treated with adjuvant chemoradiation post-operatively, and then followed regularly without evidence of disease thereafter. In light of the new CT findings, a CT-guided liver biopsy was performed at an outside institution, demonstrating poorly differentiated carcinoma. Immunohistochemical staining revealed strongly positive CK7, MOC-31, and CK/18; hepar-1 was focally positive; TTF-1, CK20, and GCDFP-15 were negative.
Literature
1.
go back to reference Goggins M et al. Pancreatic adenocarcinomas with DNA replication errors (RER+) are associated with wild-type K-ras and characteristic histopathology. Poor differentiation, a syncytial growth pattern, and pushing borders suggest RER+. Am J Pathol. 1998;152(6):1501–7.PubMed Goggins M et al. Pancreatic adenocarcinomas with DNA replication errors (RER+) are associated with wild-type K-ras and characteristic histopathology. Poor differentiation, a syncytial growth pattern, and pushing borders suggest RER+. Am J Pathol. 1998;152(6):1501–7.PubMed
2.
go back to reference Wilentz RE et al. Genetic, immunohistochemical, and clinical features of medullary carcinoma of the pancreas: a newly described and characterized entity. Am J Pathol. 2000;156(5):1641–51.PubMedCrossRef Wilentz RE et al. Genetic, immunohistochemical, and clinical features of medullary carcinoma of the pancreas: a newly described and characterized entity. Am J Pathol. 2000;156(5):1641–51.PubMedCrossRef
3.
go back to reference Lynch HT et al. Review of the Lynch syndrome: history, molecular genetics, screening, differential diagnosis, and medicolegal ramifications. Clin Genet. 2009;76(1):1–18.PubMedCrossRef Lynch HT et al. Review of the Lynch syndrome: history, molecular genetics, screening, differential diagnosis, and medicolegal ramifications. Clin Genet. 2009;76(1):1–18.PubMedCrossRef
4.
go back to reference Miller G, Schwartz LH, D’Angelica M. The use of imaging in the diagnosis and staging of hepatobiliary malignancies. Surg Oncol Clin N Am. 2007;16(2):343–68.PubMedCrossRef Miller G, Schwartz LH, D’Angelica M. The use of imaging in the diagnosis and staging of hepatobiliary malignancies. Surg Oncol Clin N Am. 2007;16(2):343–68.PubMedCrossRef
5.
go back to reference Bruix J, Sherman M. AASLD practice guideline: management of hepatocellular carcinoma. Hepatology. 2005;42(5):1208–36.PubMedCrossRef Bruix J, Sherman M. AASLD practice guideline: management of hepatocellular carcinoma. Hepatology. 2005;42(5):1208–36.PubMedCrossRef
6.
go back to reference Huitzil-Melendez FD et al. Advanced hepatocellular carcinoma: which staging systems best predict prognosis? J Clin Oncol. 2010;28(17):2889–95.PubMedCrossRef Huitzil-Melendez FD et al. Advanced hepatocellular carcinoma: which staging systems best predict prognosis? J Clin Oncol. 2010;28(17):2889–95.PubMedCrossRef
7.
go back to reference Marelli L et al. Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol. 2007;30(1):6–25.PubMedCrossRef Marelli L et al. Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol. 2007;30(1):6–25.PubMedCrossRef
8.
go back to reference Abou-Alfa GK et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2006;24(26):4293–300.PubMedCrossRef Abou-Alfa GK et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2006;24(26):4293–300.PubMedCrossRef
9.
go back to reference Cheng AL et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10(1):25–34.PubMedCrossRef Cheng AL et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10(1):25–34.PubMedCrossRef
10.
go back to reference Llovet JM et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378–90.PubMedCrossRef Llovet JM et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378–90.PubMedCrossRef
11.
go back to reference Buijs M et al. Nonresectable hepatocellular carcinoma: long-term toxicity in patients treated with transarterial chemoembolization–single-center experience. Radiology. 2008;249(1):346–54.PubMedCrossRef Buijs M et al. Nonresectable hepatocellular carcinoma: long-term toxicity in patients treated with transarterial chemoembolization–single-center experience. Radiology. 2008;249(1):346–54.PubMedCrossRef
12.
go back to reference Blanchet B et al. Toxicity of sorafenib: clinical and molecular aspects. Expert Opin Drug Saf. 2010;9(2):275–87.PubMedCrossRef Blanchet B et al. Toxicity of sorafenib: clinical and molecular aspects. Expert Opin Drug Saf. 2010;9(2):275–87.PubMedCrossRef
13.
go back to reference Riaz A et al. Imaging response in the primary index lesion and clinical outcomes following transarterial locoregional therapy for hepatocellular carcinoma. Jama. 2010;303(11):1062–9.PubMedCrossRef Riaz A et al. Imaging response in the primary index lesion and clinical outcomes following transarterial locoregional therapy for hepatocellular carcinoma. Jama. 2010;303(11):1062–9.PubMedCrossRef
14.
go back to reference Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30(1):52–60.PubMedCrossRef Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30(1):52–60.PubMedCrossRef
Metadata
Title
A Woman with Remotely Treated Pancreas Cancer and New Abdominal Pain: A Discussion of Evaluation and Management
Authors
Andrew S. Epstein
Eileen M. O’Reilly
Maeve Lowery
Ali Shamseddine
Jinru Shia
Sally Temraz
Ashwaq Al-Olayan
Mohamed Naghy
David Kelsen
Manish A. Shah
Ghassan K. Abou-Alfa
Publication date
01-12-2011
Publisher
Springer US
Published in
Journal of Gastrointestinal Cancer / Issue 4/2011
Print ISSN: 1941-6628
Electronic ISSN: 1941-6636
DOI
https://doi.org/10.1007/s12029-010-9234-0

Other articles of this Issue 4/2011

Journal of Gastrointestinal Cancer 4/2011 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.